NCT06494514 NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer
| NCT ID | NCT06494514 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Du Juan |
| Condition | Locally Advanced Pancreatic Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-04-01 |
| Primary Completion | 2027-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2024-04-01 with a primary completion date of 2027-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the study is to evaluate the efficacy and safety of NALIRINOX combined with PD-1 synchronous sequential SBRT or AG combined with PD-1 synchronous sequential SBRT as first line systematical therapy in patients with ocally advanced pancreatic cancer.
Eligibility Criteria
Inclusion Criteria: 1. Histologically or cytologically confirmed pancreatic cancer; 2. ECOG performance no more than 2; 3. Radiographically assessed as locally advanced pancreatic cancer according to NCCN guidelines; 4. No previous anti-tumor therapy； 5. Able and willing to provide a written informed consent; Exclusion Criteria: * 1\. Prior anti-tumor therapy of any kind; 2. Severe infection (\>NCI CTC grade 2); 3.Patients with autoimmune disease or immune deficiency who are treated with immunosuppressive drugs; 4.Patients with bleeding tendency; 5. Pregnant or lactating women.
Contact & Investigator
Juan Du
PRINCIPAL INVESTIGATOR
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Frequently Asked Questions
Who can join the NCT06494514 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Locally Advanced Pancreatic Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06494514 currently recruiting?
Yes, NCT06494514 is actively recruiting participants. Contact the research team at dujunglyy@163.com for enrollment information.
Where is the NCT06494514 trial being conducted?
This trial is being conducted at Nanjing, China, Nanjing, China.
Who is sponsoring the NCT06494514 clinical trial?
NCT06494514 is sponsored by Du Juan. The principal investigator is Juan Du at The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.